January 1, 2006Leukemia & lymphoma/Leukemia and lymphoma

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does a pegylated liposomal doxorubicin modified CHOP-rituximab regimen provide active treatment with reduced cardiac toxicity in elderly patients with diffuse large B-cell lymphoma?

Population

30 untreated elderly patients with diffuse large B-cell lymphoma, median age 69 years.

Design

Case_series

Follow-up

Projected 2 years

Authors

FZFrancesco Zaja VTValentina Tomadini AZAlfonso Zaccaria

Discussion

Member takes

Overview

Supports evaluation of liposomal doxorubicin regimens in elderly DLBCL; hypothesis-generating pending randomized confirmation of efficacy and safety.

Structured PICO

Does a pegylated liposomal doxorubicin modified CHOP-rituximab regimen provide active treatment with reduced cardiac toxicity in elderly patients with diffuse large B-cell lymphoma?

Population

30 untreated elderly patients with diffuse large B-cell lymphoma (B-DLCL), median age 69 years (range 60 - 75 years).

Intervention

Pegylated liposomal doxorubicin (PL-doxorubicin) 30 mg/m2 in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (CHOP-R regimen) every 21 days for six courses.

Outcome

Overall response rate, complete response rate, and cardiac toxicity (evaluated by LVEF and serum troponin-I levels).safety

A modified CHOP-rituximab regimen using pegylated liposomal doxorubicin is active and associated with negligible cardiac toxicity in elderly patients with diffuse large B-cell lymphoma.

Cite This Study

Zaja et al. (2006) studied this question.

synapsesocial.com/papers/6a7a64441ba4614d7ff3e42d https://doi.org/10.1080/10428190600799946

View Full Paper

Ask AI

Bookmark

January 1, 2006Leukemia & lymphoma/Leukemia and lymphoma

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does a pegylated liposomal doxorubicin modified CHOP-rituximab regimen provide active treatment with reduced cardiac toxicity in elderly patients with diffuse large B-cell lymphoma?

Population

30 untreated elderly patients with diffuse large B-cell lymphoma, median age 69 years.

Design

Case_series

Follow-up

Projected 2 years

Authors

FZFrancesco Zaja VTValentina Tomadini AZAlfonso Zaccaria

Discussion

Member takes

Overview

Supports evaluation of liposomal doxorubicin regimens in elderly DLBCL; hypothesis-generating pending randomized confirmation of efficacy and safety.

Structured PICO

Does a pegylated liposomal doxorubicin modified CHOP-rituximab regimen provide active treatment with reduced cardiac toxicity in elderly patients with diffuse large B-cell lymphoma?

Population

30 untreated elderly patients with diffuse large B-cell lymphoma (B-DLCL), median age 69 years (range 60 - 75 years).

Intervention

Pegylated liposomal doxorubicin (PL-doxorubicin) 30 mg/m2 in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (CHOP-R regimen) every 21 days for six courses.

Outcome

Overall response rate, complete response rate, and cardiac toxicity (evaluated by LVEF and serum troponin-I levels).safety

A modified CHOP-rituximab regimen using pegylated liposomal doxorubicin is active and associated with negligible cardiac toxicity in elderly patients with diffuse large B-cell lymphoma.

Cite This Study

Zaja et al. (2006) studied this question.

synapsesocial.com/papers/6a7a64441ba4614d7ff3e42d https://doi.org/10.1080/10428190600799946

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark